HOME >> MEDICINE >> NEWS
Controversial drug shown to act on brain protein to cut alcohol use

A naturally occurring hallucinogen advocated by some clinicians as a potent anti-addiction drug has been rigorously studied for the first time, confirming its ability to block alcohol craving in rodents, and clarifying how it works in the brain. The new research findings about the drug Ibogaine open the way for development of other drugs to reverse addiction without Ibogaine's side effects, potentially adding to the small arsenal of drugs that effectively combat addiction.

Derived from a West African shrub, Ibogaine has been championed for years by a cadre of clinicians and drug treatment advocates impressed with its ability to reverse withdrawal symptoms and craving for alcohol and various drugs of abuse. It has been used outside of the U.S. to treat addiction by American and other clinicians. But its side effects, including hallucinations, which made it popular in the 1960s drug culture, and evidence of toxicity to certain nerve cells in rodent studies have discouraged careful studies of its clinical potential against drug and alcohol addiction. The FDA has not approved use of Ibogaine in the U.S.

Scientists at UCSF's Ernest Gallo Clinic and Research Center have now shown definitively in experiments with mice and rats that Ibogaine does reduce alcohol consumption, and they have determined that it does so by increasing the level of a brain protein known as glial cell line-derived neurotrophic factor, or GDNF. In a separate study, they demonstrated that GDNF by itself decreases alcohol consumption.

The research is being published in the January 19 issue of The Journal of Neuroscience.

"By identifying the brain protein that Ibogaine regulates to reduce alcohol consumption in rats, we have established a link between GDNF and reversal of addiction -- knowledge of a molecular mechanism that should allow development of a new class of drugs to treat addiction without Ibogaine's side effects," said Dorit Ron, PhD, UCSF associate professor of
'"/>

Contact: Wallace Ravven
wravven@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
18-Jan-2005


Page: 1 2 3

Related medicine news :

1. Controversial Atkins Diet may be beneficial for people with epilepsy
2. Controversial performance enhancer "andro" affects brains as well as brawn, say UMass researchers
3. Cartilage repair techniques shown to restore patient mobility and reduce pain
4. Sprinklers shown effective in slowing dorm fires
5. HPV vaccine shown effective at reducing cancer-causing infections
6. HPV vaccine shown to substantially reduce cervical cancer
7. New research results: Heart jacket shown to be effective
8. Pioglitazone shown to reverse thickening of carotid artery wall
9. Isolated soy protein shown to benefit type 2 diabetics, study indicates
10. Pioglitazone HCI shown to lower blood pressure in hypertensive patients with type 2 diabetes
11. Increased risk of cardiovascular disease shown in PCOS patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Controversial drug shown act brain protein cut alcohol use

(Date:4/27/2015)... (PRWEB) April 27, 2015 Covenant Care, ... nationwide, has rolled out its “Enhanced Dining” service with ... foods developed with input from residents, patients and families ... and the redesign of its dining rooms so that ... the quality of life for our residents is our ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 The ... both inpatient and outpatient therapy facilities that provide physical, ... years to 2015, the industry has experienced revenue growth ... acceptance of the benefits of physical therapy services. The ... helped support industry revenue growth during the period because ...
(Date:4/26/2015)... Indiana Fiber Network, LLC (IFN), the leading Indiana ... Company has selected IFN as a fiber transport provider. ... Mutual Insurance Company states: “IFN’s broadband fiber solution created ... We were interested in building entrance and ... ensure we achieved both. ” , According ...
(Date:4/26/2015)... India Network Foundation, a non-profit organization in ... to the Asian Indian community in the United States ... than two decades. The India News Network Digest of ... the world with the latest news items from India, ... Law Forum Digest, edited and contributed by Sheela Murthy, ...
(Date:4/26/2015)... The grand celebration got off to a festive start with ... Deb then introduced Sandy Valentine, the wife of CCAR’s Executive ... his Walk for Recovery on the Appalachian Trail. ... gratitude to the volunteers via video. Board President Tom Kirk ... CCAR’s mission. Volunteer Manager Conrad Sienkiewicz read the names ...
Breaking Medicine News(10 mins):Health News:Covenant Care Rolls Out "Enhanced Dining" Offering Restaurant Style Experience To Residents, Patients & Families 2Health News:Physical Therapy Rehabilitation Centers in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Physical Therapy Rehabilitation Centers in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 3Health News:The Connecticut Community for Addiction Recovery (CCAR) honors its volunteers during National Volunteer Recognition Week. 2
(Date:4/24/2015)... -- Hospira, Inc. (NYSE: HSP ), ... spoke about the importance of extrapolation in bringing biosimilars ... annual European Biosimilars Group conference in London ... publication of a pivotal white paper titled, "Why ... biosimilars." Speaking at the EGA conference, ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... 23, 2015 Once again, BeaconMedaes is meeting ... to patient safety. BeaconMedaes, priority is to ... disease. The next generation Zone Valve Box ... are now mounted in the assembly, allowing for ease ... ceiling tiles potentially releasing dust spores and other bacteria ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2
Cached News: